Codi QR

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

Abstract Background Epidermal growth factor receptor (EGFR) mutations represent one of the most frequent oncogenic driver in non-small cell lung cancer (NSCLC). Amivantamab, a bispecific antibody targeting EGFR and MET proto-oncogene, receptor tyrosine kinase (MET), has demonstrated clinical benefit...

Descripció completa

Guardat en:
Autors principals: Ryo Yoshichika, Fumiaki Mukohara, Kotaro Yamada, Joji Nagasaki, Hiroko Watanabe, Youki Ueda, Ken Suzawa, Kazuhiko Shien, Shinichi Toyooka, Takamasa Ishino, Yosuke Togashi
Format: Artigo
Idioma:Inglês
Publicat: Springer 2026-03-01
Col·lecció:Cancer Immunology, Immunotherapy
Matèries:
Non-small cell lung cancer
Amivantamab
Antitumor immunity
EGFR
MET
Accés en línia:https://doi.org/10.1007/s00262-026-04369-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars